Exact Sciences

We’re excited to share that the first patient has been enrolled in a multi-year study for molecular residual disease (MRD) in partnership with Flatiron Health. This study will be integrated into routine care visits, generating additional clinical evidence for the Oncodetect™ test and promoting better patient outcomes. Learn more: https://lnkd.in/gAWdAznZ

Cancer touches all of us. It’s important to understand risk factors and talk with your health care provider about steps to get ahead of this disease. This #WorldCancerDay, our #ExactSciencesAthletes are raising awareness for cancer and sharing their own experiences. Watch below. #UnitedbyUnique Wisconsin Athletics

We will achieve our purpose of eradicating cancer only if we support each individual and community faced with cancer. This #WorldCancerDay, we honor the unique stories and experiences of those impacted and stand united in the fight against this disease. Discover more: https://lnkd.in/drnuZeE #UnitedByUnique

The #MCEDAct was introduced in the U.S. House and Senate last week! This bipartisan legislation aims to improve future equitable access to new and innovative cancer screenings among Medicare beneficiaries in order to increase early detection of more cancers for more individuals. “The evidence overwhelmingly supports that detecting cancer earlier can be the difference between life and death," says Lisa A. Lacasse, president of American Cancer Society Cancer Action Network (ACS CAN). "When cancer is detected at an earlier stage, it is often easier and less costly to treat, and patients are more likely to survive. We also know that the risk of developing cancer increases with age as do the odds of developing an invasive form of cancer. This legislation, for which ACS CAN has long advocated, creates a pathway to ensure timely Medicare coverage of new, innovative multi-cancer screening tests after FDA approval and clinical benefit has been shown. This legislation can greatly expand access to early detection." Read more: https://lnkd.in/eG4Bv7Ek #EarlyDetection #CancerAdvocacy #CancerScreening #Medicare

We have the opportunity to challenge the status quo in the early detection of cancer with the #MCEDAct.    Today we celebrate its reintroduction thanks to Reps. Jodey C. Arrington (R-Texas), Terri Sewell (D-Ala.), Richard Hudson (R-N. C.), Raul Ruiz (D-Calif.), Mariannette Miller-Meeks (R-Iowa) and Robin Kelly (D-Ill.) and Sens Mike Crapo (R-Idaho), Mike Bennet (D-Colo.), Tim Scott (R-S.C.) and Ron Wyden (D-Ore.).     With over 500 advocacy organizations supportive of its passage, the time is now for Congress to act and revolutionize how we detect cancer. https://lnkd.in/e-9HaUdW

I’m excited to attend and speak at the 24th PMWC - Precision Medicine World Conference (#PMWC25), co-hosted by Stanford and University of California, San Francisco at the Santa Clara Convention Center February 5 to 7. I am looking forward to discussing Precision Liquid Biopsies with Arnaud PAPIN and Elizabeth O'Donnell, MD, DipABLM and Multi-Cancer Early Detection (#MCED) with Peter B., Joshua Cohen, Eric A. Klein, MD, and Lauren C. Leiman. I’m equally eager to hear from and learn from the other exceptional speakers. With over 400 speakers, 12 tracks, and a roster of distinguished honorees, PMWC 2025 will be a unique opportunity to exchange ideas, forge new collaborations, and help advance the future of precision medicine.  #PMWC25 Tal Behar https://lnkd.in/gfxkakhB

30 days until the 2025 Cologuard Classic by Exact Sciences! Yesterday, 2024 tournament champion Joe Durant kicked things off with a live drawing out of the iconic conquistador helmet trophy to select his colon cancer honoree for this year’s tournament. He will be competing in memory of Jasmine’s mother. We’ll see everyone back in Tucson in March! #CologuardClassic

Despite declining cancer mortality rates, rising cancer incidence among younger adults and women makes cancer prevention, detection and personalized care more important than ever. This year, let’s continue to work together to raise cancer awareness and encourage individuals to talk to a health care professional about getting screened! Read more via American Cancer Society's annual report: https://bit.ly/3EfTu59

We’re sharing insights at the ASCO Gastrointestinal Cancers Symposium that provide a look at data for our upcoming Oncodetect™ molecular residual disease (MRD) test and confirm the impact of Cologuard® screening through prevention, detection, and high test completion rates. https://bit.ly/40Ihjvg #GI25

Positive top-line results from two clinical trials validate the ability of our upcoming Oncodetect™ test to detect molecular residual disease and predict recurrence in colorectal cancer patients. Learn more: https://bit.ly/3PMgB9U